Retatrutide Side Effects

Retatrutide Side Effects. Retatrutide side effects from clinical trials 2026: nausea incidence, diarrhea, stomach cramps, and safety risks from Phase 2 and TRIUMPH Phase 3 data. Key Takeaways Gastrointestinal events are the most common adverse effects: Nausea, diarrhea, and vomiting were reported in 40–67% of participants at higher doses in published Phase 2 trial data Adverse events are dose-dependent: Higher retatrutide doses consistently produced higher rates of GI events across all published trials Most adverse events were mild to moderate: The Phase 2 trial reported the majority of events as Grade 1-2 in severity Discontinuation rates ranged from 6–10%: Published data shows dropout rates due to adverse events were comparable to other GLP-1 class compounds Retatrutide is not FDA-approved: All safety data comes from investigational clinical trials — it remains a research compound What Clinical Trials Tell Us About Retatrutide Adverse Events Retatrutide (LY3437943) is an investigational triple-agonist peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. As a first-in-class triple agonist, its adverse event profile is of particular interest to researchers because the glucagon receptor component adds a mechanism not present in existing dual-agonist compounds like tirzepatide. All adverse event data in this article comes from two sources: the Phase 2 trial published in the New England Journal of Medicine (Jastreboff et al., 2023) and the TRIUMPH Phase 3 program data presented at medical conferences. This article does not include anecdotal reports, off-label observations, or non-peer-reviewed sources. For the complete regulatory timeline and trial program overview, see our Retatrutide Approval Status 2026 tracker. Researchers comparing current lab supply options can also review our Retatrutide product page . For timing expectations, see our how long retatrutide takes to work timeline . Because retatrutide is a triple agonist that shifts blood sugar, lipids, heart rate, and other markers at once, the safest way to use it is to watch those numbers move. Our free peptide cheat sheet covers the metabolic, cardiovascular, and organ markers most affected — measured before you start and again each cycle. Phase 2 Trial Adverse Event Data (NEJM, 2023) The pivotal Phase 2 trial (n=338) randomized participants across multiple dose levels over 48 weeks. This trial provides the most detailed published adverse event data currently available for retatrutide. Overall Adverse Event Rates Dose Group Any Adverse Event (%) GI Adverse Events (%) Discontinuation Due to AE (%) Placebo 72.1% 32.6% 0% 1 mg 88.6% 48.6% 2.9% 4 mg (escalated) 88.6% 60.0% 5.7% 4 mg (single dose) 90.9% 63.6% 6.1% 8 mg (escalated) 87.5% 57.5% 5.0% 8 mg (single dose) 88.6% 62.9% 5.7% 12 mg (escalated) 97.2% 66.7% 8.3% Source: Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. Key Observations from Phase 2 Data Dose escalation reduced adverse events: Groups that used gradual dose titration reported fewer GI events than those starting at the target dose directly No deaths were attributed to the study drug Serious adverse events were reported at low rates across all groups, with no clear dose-dependent pattern for serious events The placebo group also reported substantial adverse events (72.1%), which is typical for trials of this size and duration TRIUMPH Phase 3 Adverse Event Profiles The TRIUMPH program consists of eight Phase 3 trials evaluating retatrutide across multiple indications including obesity, type 2 diabetes, and metabolic-associated steatotic liver disease (MASLD). While complete adverse event data from most TRIUMPH trials is still pending full publication, early reported data aligns with Phase 2 observations. TRIUMPH-4 (Completed December 2025) TRIUMPH-4, the largest cardiovascular outcomes trial, met all primary and key secondary endpoints. Preliminary safety reporting indicated: GI adverse event profile consistent with Phase 2 data No new safety signals identified beyond those observed in earlier trials Discontinuation rates due to adverse events were comparable to other GLP-1 class trials Full adverse event tables from TRIUMPH-4 are expected with the peer-reviewed publication. For the complete trial timeline, see our Retatrutide Approval Status 2026 guide. Common Adverse Events Researchers Track in Phase 2 and Phase 3 Across retatrutide side effects clinical trials queries, the same adverse-event cluster appears repeatedly: nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal pain, back pain, and fatigue or tiredness. The most detailed published percentages still come from the 48-week Phase 2 trial, while the TRIUMPH Phase 3 program is the source researchers are watching for larger-sample confirmation of common adverse events, discontinuation rates, and rare safety signals. For the specific query retatrutide back pain adverse event trial , the important context is that back pain was documented as a lower-frequency adverse event in the published Phase 2 data, separate from gastrointestinal abdominal pain. Researchers also search for retatrutide clinical trial adverse events fatigue and retatrutide phase 2 trial adverse events fatigue ; fatigue/tiredness appears in the broader tolerability profile but was not the dominant safety signal compared with GI events. In short, the retatrutide clinical trials side effects safety profile remains GI-led, dose-related, and still incomplete at long duration. Searches for retatrutide common side effects 2025 2026 should be interpreted through the available published Phase 2 trial and the still-emerging TRIUMPH Phase 3 safety data. Related queries such as retatrutide long-term safety data 2026 , retatrutide common adverse events phase 3 trials , retatrutide phase 2 trial adverse events abdominal pain back pain , and retatrutide clinical trial side effects safety profile all point to the same limitation: Phase 2 gives the most detailed published table, while Phase 3 is still becoming fully available. As of 2026, the retatrutide long-term safety data remains incomplete because Phase 3 results have not all been fully peer-reviewed in journal form. That means any retatrutide safety profile discussion should separate published Phase 2 adverse event data from emerging Phase 3 safety updates and avoid treating preliminary conference or registry updates as final prescribing-level evidence. Adverse Events by System Gastrointestinal Events GI adverse events are the most commonly reported class across all retatrutide clinical trials. This is consistent with the GLP-1 receptor agonist mechanism, which slows gastric emptying and affects appetite signaling. Event Phase 2 Rate (12 mg group) Phase 2 Rate (Placebo) Nausea 45.8% 11.6% Diarrhea 33.3% 9.3% Vomiting 22.2% 2.3% Constipation 16.7% 7.0% Decreased appetite 22.2% 2.3% The nausea incidence at the highest dose — a nausea percentage of roughly 46% — makes it the single most reported adverse event in retatrutide clinical trials 2026 data. Does retatrutide cause diarrhea? Yes: the Phase 2 trial recorded diarrhea in about 33% of the 12 mg group, along with stomach cramps, upset stomach, and stomach ache reports that fall under the broader GI category. Back pain and tiredness were also documented at low rates across dose groups. Onset pattern: Published data indicates most GI events occurred during the dose-escalation phase and diminished over time as participants continued at stable doses. This transient pattern is well-documented across the GLP-1 agonist class. For a deeper look at abdominal discomfort specifically, including management strategies and dose-dependent pain patterns, see our stomach pains on reta research guide. Hepatobiliary Events Gallbladder-related adverse events have been observed in retatrutide trials, consistent with observations across GLP-1 agonist studies more broadly. Rapid weight loss from any cause is a known risk factor for gallstone formation. Cholelithiasis (gallstones) was reported at low rates in the Phase 2 trial Incidence was slightly higher in higher-dose groups, though absolute numbers were small This observation is not unique to retatrutide — semaglutide and tirzepatide trials also reported gallbladder events Cardiovascular Observations Heart rate changes were documented in clinical trial participants: Small mean increases in heart rate (2-4 bpm) were observed in active treatment groups This is consistent with GLP-1 agonist class effects — semaglutide and tirzepatide produce similar heart rate increases No increased rate of major adverse cardiovascular events (MACE) was observed in Phase 2 TRIUMPH-4 is specifically designed to evaluate cardiovascular outcomes at scale Injection Site Reactions As a subcutaneous injectable, injection site reactions were reported: Injection site erythema, pain, and pruritus were documented at low rates Most injection site events were Grade 1 (mild) No injection site reactions led to treatment discontinuation in published data How Retatrutide Adverse Events Compare to Other GLP-1 Compounds Comparing adverse event profiles across different trials has significant limitations — patient populations, dose ranges, and endpoint definitions vary. However, published data allows a directional comparison of the most common GI events: Adverse Event Retatrutide (12 mg) Semaglutide 2.4 mg (STEP trials) Tirzepatide 15 mg (SURMOUNT trials) Nausea ~46% ~44% ~31% Diarrhea ~33% ~30% ~23% Vomiting ~22% ~24% ~12% Constipation ~17% ~24% ~12% Important caveat: These numbers come from different trial populations and cannot be directly compared. The comparison is included for directional context only. For a deeper dive into compound differences, see our Retatrutide vs Tirzepatide vs Semaglutide research comparison. Dose-Dependent Adverse Event Patterns One of the clearest findings from published retatrutide data is the dose-dependent relationship with adverse events: Lower doses (1 mg): GI event rates only modestly above placebo Mid-range doses (4-8 mg): GI event rates of 57-64%, with dose escalation reducing peak incidence Highest dose (12 mg): GI event rates of ~67%, though most events were mild-to-moderate and transient The Phase 2 trial included both "single-dose" and "escalated-dose" cohorts for the 4 mg and 8 mg groups. The escalated groups — where participants started at lower doses and titrated up over weeks — consistently reported fewer GI events than the single-dose groups. This finding has informed the dose-escalation protocols used in the TRIUMPH Phase 3 program. Discontinuation Rates in Clinical Trials Treatment discontinuation due to adverse events is a key measure of tolerability. Published Phase 2 data shows: Dose Group Discontinuation Due to AE Placebo 0% 1 mg 2.9% 4 mg (escalated) 5.7% 8 mg (escalated) 5.0% 12 mg (escalated) 8.3% For context, discontinuation rates in semaglutide 2.4 mg trials (STEP program) were approximately 7%, and tirzepatide 15 mg trials (SURMOUNT) reported approximately 6-7%. Retatrutide discontinuation rates at the highest dose are modestly higher but broadly comparable to the GLP-1 agonist class. Frequently Asked Questions What are the most common retatrutide side effects? Based on published Phase 2 trial data, the most common adverse events are gastrointestinal: nausea (up to 46%), diarrhea (up to 33%), vomiting (up to 22%), and decreased appetite (up to 22%). These rates are from the highest dose group (12 mg) and are lower at reduced doses. Is retatrutide safe? Retatrutide is an investigational compound — it has not received FDA approval, and its long-term safety profile is still being evaluated through the TRIUMPH Phase 3 program. Published Phase 2 data showed no unexpected safety signals, but the compound remains under regulatory review. For general peptide safety information, see our Are Research Peptides Safe? guide. Are retatrutide side effects worse than semaglutide? Published trial data suggests retatrutide GI adverse event rates at higher doses are broadly comparable to semaglutide. Nausea rates (~46% vs ~44%) are similar, while diarrhea may be slightly more common with retatrutide. However, cross-trial comparisons are inherently limited. For a detailed comparison, see our Retatrutide vs Semaglutide research guide. Do retatrutide side effects go away? Published data indicates most GI adverse events were transient, occurring primarily during the dose-escalation phase. Participants who continued at stable doses generally reported diminishing GI symptoms over time. This pattern is consistent with GLP-1 agonist class compounds. Does dose escalation reduce retatrutide side effects? Yes. The Phase 2 trial demonstrated that gradual dose titration reduced the incidence of GI adverse events compared to starting at the target dose directly. This finding is reflected in the dose-escalation protocols of the TRIUMPH Phase 3 program. What about long-term retatrutide side effects? Long-term safety data beyond 48 weeks (Phase 2 duration) is still being generated through the TRIUMPH Phase 3 trials. Until these results are fully published and peer-reviewed, the long-term adverse event profile remains incompletely characterized. Conclusion Published clinical trial data paints a consistent picture of the retatrutide adverse event profile and associated risks: GI events are common, dose-dependent, and generally transient , with rates comparable to other GLP-1 class compounds. The unique triple-agonist mechanism (GLP-1 + GIP + glucagon) has not produced unexpected safety signals beyond those anticipated from the individual receptor mechanisms. As the TRIUMPH Phase 3 program data is published, the adverse event profile will become more complete — particularly for long-term safety, cardiovascular outcomes, and rare events that require large sample sizes to detect. Track the latest: Our Retatrutide Approval Status 2026 article tracks TRIUMPH trial readouts and regulatory filings as they're announced. Compare compounds: See our Retatrutide vs Semaglutide and Retatrutide vs Tirzepatide vs Semaglutide research comparisons for receptor profile and efficacy data. References Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 adverse event profile. N Engl J Med . 2023;389:514-526. PubMed Rosenstock J, et al. Retatrutide in type 2 diabetes: Phase 2 safety and tolerability data. Lancet . 2023;402(10401):529-544. PubMed Sanyal AJ, et al. Retatrutide for MASLD: hepatic safety and adverse events. Nat Med . 2024;30:2037-2048. PubMed ClinicalTrials.gov. TRIUMPH-1: Retatrutide in Obesity (long-term safety endpoints). NCT05882045 ClinicalTrials.gov. TRIUMPH-3: Retatrutide and Cardiovascular Outcomes. NCT05882487 U.S. Food and Drug Administration. GLP-1 receptor agonist class safety information. fda.gov drug safety Reconstitution math: Use our free Peptide Calculator to determine concentration, syringe units, and doses per vial for your research protocols. Browse catalog: See all available research compounds in our peptide catalog . Disclaimer: This article reports on published clinical trial data for informational and educational purposes only. It does not constitute medical advice. Retatrutide is an investigational compound not approved by the FDA for any indication. All products referenced are intended for laboratory and research use only. Not for human consumption. Related reading: CagriSema vs Retatrutide: Obesity Peptides Compared PeptideStack page context: visitors can use the header navigation to reach the product catalog, blog, calculators, supplier pages, discount-code pages, contact page, legal policies, shipping policy, refund policy, privacy policy, terms, and research disclaimer. The site is organized around research peptide education, supplier transparency, product comparison, vendor review content, discount-code tracking, and calculator tools for reconstitution or unit conversion research planning. PeptideStack separates research-use-only peptide information from FDA-approved medication and licensed telehealth pathways. Research peptide pages are informational and are not medical advice, prescription guidance, dosing instructions, treatment recommendations, or instructions for human consumption. Many pages include affiliate disclosures because PeptideStack may earn a commission when visitors click external supplier or telehealth links. That commission does not change the price paid by visitors and does not mean PeptideStack manufactures, sells, distributes, compounds, or ships peptides or medications. Supplier and product pages should be evaluated for third-party testing, batch-specific certificates of analysis, named laboratory verification, transparent pricing, realistic delivery expectations, payment security, refund policies, support quality, and consistent research-use-only labeling. Blog pages connect related guides, comparison articles, FDA approval status explainers, safety context, legality resources, product pages, vendor reviews, and calculator tools so visitors can keep researching without relying on a single supplier claim. Calculator pages are educational tools for laboratory planning and should be cross-checked against professional protocols, institutional requirements, and applicable laws. Legal and disclaimer pages explain the boundaries of PeptideStack content and the responsibility of visitors who evaluate third-party vendors. The rendered interface may add interactive details such as mobile navigation labels, product tabs, share buttons, related article cards, disclosure boxes, call-to-action buttons, vendor selectors, copy-code controls, email-code forms, footer navigation, and status labels. The static HTML fallback includes this context so the same page purpose is understandable before the JavaScript application finishes loading. Visitors should treat PeptideStack as a research and comparison starting point. Final supplier evaluation should include direct review of the external vendor website, current product availability, checkout terms, applicable laws, institutional requirements, and any third-party laboratory documentation available for the exact product or batch being considered. Footer resources repeat important sitewide context: PeptideStack is independent, affiliate-supported, research-focused, and not a pharmacy or manufacturer. Pages may include links to the iOS app, calculators, blog hubs, product hubs, supplier comparisons, support contact, and policy documents. This repeated context is intentionally available in the raw HTML for crawlers that inspect a page before executing the React bundle. Raw HTML also includes page summaries for mobile crawlers using JavaScript rendering, desktop crawlers comparing source to rendered output, accessibility tools, and no-script visitors. The fallback is replaced by the React app in normal browsers but keeps the source document aligned with the visible page topic. This fallback keeps source HTML and rendered HTML closer for crawl diagnostics and SEO audits across crawled pages, routes, reports, and recrawls.